Clinical assessment of asthma progression in children and adults

Asthma is a heterogeneous disorder with a variable course, characterized by episodes of cough, wheezing and shortness of breath, reversible airflow limitation, and bronchial hyperresponsiveness. It begins early in life in many subjects with intermittent symptoms occurring with viral respiratory trac...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 121; no. 3; pp. 548 - 557
Main Authors Spahn, Joseph D., Covar, Ronina
Format Journal Article
LanguageEnglish
Published New York, NY Mosby, Inc 01.03.2008
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0091-6749
1097-6825
1097-6825
DOI10.1016/j.jaci.2008.01.012

Cover

More Information
Summary:Asthma is a heterogeneous disorder with a variable course, characterized by episodes of cough, wheezing and shortness of breath, reversible airflow limitation, and bronchial hyperresponsiveness. It begins early in life in many subjects with intermittent symptoms occurring with viral respiratory tract infections. Over time, and in genetically susceptible children (those with an atopic predisposition), the disease becomes more persistent with symptoms occurring in the absence of respiratory tract infections. Children with persistent wheezing are eventually diagnosed with asthma, with those at greatest risk having developed allergic sensitization early in life. Among children with asthma, some will have lifelong asthma with active symptoms and progressive loss of lung function over time, whereas other children will undergo asthma remission in adolescence. Once in remission, the disease may remain quiescent, or it may relapse in midadult life. This review focuses on studies that have enhanced our understanding of the progression of asthma from infancy to adulthood. Studies evaluating progressive loss of lung function, the best-studied measure of asthma progression, are also reviewed, followed by a brief discussion of whether asthma progression can be modified by inhaled glucocorticoid therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Review-3
ISSN:0091-6749
1097-6825
1097-6825
DOI:10.1016/j.jaci.2008.01.012